Shots:

• In a P-I study- patients were treated initially for 14wks. with UV1 + pembrolizumab and patient in the first cohort had been followed for at least 24mos. from the start of their treatment- @ cut-off date of Oct 12- 2021
• After @2yrs. follow up- OS (80%) in the first cohort of 20 patients. mPFS (18.9mos.). The 24mos. follow-up data compares favorably with an earlier large-scale study of pembrolizumab alone that demonstrated an OS rate of 58% after 24mos. and mPFS of 5.5-11.6mos.
• The 2yrs. follow-up data suggested that the way in which UV1 mobilizes the immune system provides long benefits to the patients

  | Ref: Globe Newswire | Image: Businesswire